Clementia Pharmaceuticals

Image of a neon sign with the word no lit up next to an unlit yes

Biotech

Ipsen's rare disease candidate rejected after mounting delays

Ipsen is racing to answer the FDA's questions regarding its rare disease med palovarotene after the agency rejected the company's application.

Max Bayer Dec 27, 2022 10:44am

calendar hour glass wait delay months

Ipsen's rare disease med palovarotene faces another delay

Oct 25, 2022 4:03pm

Medical examination and growth graph data of business on tablet with doctors health report clipboard on background

Congruence to build team of 'drug hunters' with $50M funding

Feb 8, 2022 8:00am

ax splitting wood

Ipsen scraps pivotal trial as partial clinical hold drags on

Mar 26, 2020 8:45am

Regeneron HQ

Regeneron's rare bone disease drug delivers in phase 2

Jan 9, 2020 10:38am

Ipsen CEO David Meek

Ipsen strikes $1.3B Clementia buyout to boost rare disease unit

Feb 25, 2019 10:45am